Supernus Pharmaceuticals has acquired Sage Therapeutics, strengthening its neuropsychiatry product portfolio.

A new report compiles the latest data and insight on scaling cell and gene therapy (CGT) effectively to improve patient access.

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

Major pharma manufacturers have a 29 September deadline to adjust their drug prices relative to other developed countries.

BeOne Medicines' investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, has received priority medicines (PRIME) designation.

Tidmarsh will temporarily guide CBER’s regulatory activities while the FDA searches for a permanent department lead.

Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.